Skip to main content

Table 4 Dosimetric changes affected by tumor regression and baseline obstructive pneumonitis/atelectasis

From: Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy

Variables Relative change (median) # Proportion of patients achieving above 5% reduction/increase*
Tumor regression [quick(n = 13) vs. slow(n = 14)] Obstructive pneumonitis/atelectasis [Yes(n = 11) vs. No(n = 16)] Tumor regression [quick(n = 13) vs. slow(n = 14)] Obstructive pneumonitis/atelectasis [Yes(n = 11) vs. No(n = 16)]
PTV-GTV
 V51 0.2% vs. -0.7%(P = 0.185) −0.3% vs. -0.1%(P = 0.394) 7.7% vs. 14.3%(P = 0.593) 10% vs. 11.8%(P = 0.89)
 D95 0.3% vs. -0.1%(P = 0.867) −0.05% vs. 0.4%(P = 0.942) 0% vs. 7.1%(P = 0.335) 10% vs. 0%(P = 0.192)
Total lung
 Dmean 2.2% vs. 0.2%(P = 0.009) 2.3% vs. 0.4%(P = 0.023) 7.7% vs. 0%(P = 0.299) 9.1% vs. 0%(P = 0.228)
 V20 2.7% vs. 0.5%(P = 0.006) 3.3% vs. 0.9%(P = 0.110) 23.1% vs. 0(P = 0.061) 9.1% vs. 12.5%(P = 0.786)
 V30 3.5% vs. 0.2%(P = 0.022) 3.9% vs. 0.2%(P = 0.039) 38.5% vs. 7.1%(P = 0.055) 36.4% vs. 12.5%(P = 0.150)
Esophagus
 Dmean 2.2% vs. 0.2%(P = 0.009) 2.3% vs. 0.4%(P = 0.023) 7.7% vs. 0%(P = 0.299) 9.1% vs. 0%(P = 0.228)
 Dmax 4.0% vs 5.0%(P = 0.239) 3.2% vs. 4.8%(P = 0.272) 23.1% vs. 50%(P = 0.155) 27.3% vs. 43.8%(P = 0.393)
Heart
 Dmean 0.1% vs. 0.8%(P = 0.488) 3.9% vs. 0.2%(P = 0.251) 38.5% vs. 0%(P = 0.012) 36.4% vs. 6.3%(P = 0.046)
 V30 −5.2% vs. -1.7%(P = 0.375) 8.1% vs. -5.2%(P = 0.162) 38.5% vs. 14.3%(P = 0.16) 54.5% vs. 6.3%(P = 0.006)
 V40 −16.1% vs. -5.7%(P = 0.458) 2.1% vs. -16.1%(P = 0.272) 30.8% vs. 28.6%(P = 0.902) 45.5% vs. 18.8%(P = 0.143)
  1. #Relative change = (Accumulated plan-Original plan)/Original plan×100%
  2. *proportion of patients who had above 5% reduction in PTV-GTV dosage or above 5% increase in OARs dosage
\